Belite Bio's Tinlarebant Approval Review Gets Three More Months — FDA Targets May 2027

The oral retinal-disease candidate met its main goal in a completed late-stage Stargardt trial.

Share
Belite Bio's Tinlarebant Approval Review Gets Three More Months — FDA Targets May 2027

Belite Bio, a developer of drugs for degenerative retinal diseases, reported Friday that the FDA extended tinlarebant's approval review by three months. Its announcement, furnished to the U.S. Securities and Exchange Commission, puts the revised target decision date at May 12, 2027.

A Longer Wait For Stargardt

The application seeks approval to treat Stargardt disease type 1. Belite Bio attributed the extension to the FDA needing additional time to evaluate information supporting the application.

Management said it remains confident in the clinical evidence for tinlarebant and intends to keep working closely with the agency throughout its assessment. The FDA has not decided whether to approve the drug.

The FDA plans to send proposed labeling requests and any anticipated requirements for monitoring or studies after approval, if necessary, by April 12, 2027. That step depends on the ongoing review finding no major deficiencies.

The Lead Drug's Clinical Record

Tinlarebant is Belite Bio's lead candidate. A completed late-stage trial involving adolescents and adults with Stargardt disease type 1 met its main goal.

Another mid-to-late-stage trial is evaluating the candidate in adolescents and adults with the same disease. A separate late-stage study covers geographic atrophy, the advanced form of dry age-related macular degeneration.

The oral treatment is designed to limit toxic compounds derived from vitamin A that build up in the eye. It lowers levels of retinol binding protein 4, which carries vitamin A from the liver to the eye. Reducing that supply is intended to curb formation of the toxins involved in Stargardt disease and geographic atrophy's progression.

Tinlarebant has received U.S. Breakthrough Therapy designation, as well as Fast Track and Rare Pediatric Disease designations for Stargardt disease type 1. It also holds Orphan Drug designations in the U.S., Europe, Japan and Switzerland, and Japan's Sakigake designation.

Belite Bio also develops treatments for specific metabolic diseases. Its market value was $6.1 billion ahead of Friday's U.S. session.

May 12, 2027, is now the FDA's target for acting on Belite Bio's Stargardt application.

Sources